In the preceding three months, 5 analysts have released ratings for Exact Sciences EXAS, presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Exact Sciences, presenting an average target of $88.2, a high estimate of $91.00, and a low estimate of $80.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.16%.
Diving into Analyst Ratings: An In-Depth Exploration
A comprehensive examination of how financial experts perceive Exact Sciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Bruce Jackson | Benchmark | Announces | Buy | $91.00 | - |
| Subbu Nambi | Guggenheim | Announces | Buy | $90.00 | - |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $90.00 | $100.00 |
| David Westenberg | Piper Sandler | Lowers | Overweight | $80.00 | $90.00 |
| David Westenberg | Piper Sandler | Announces | Overweight | $90.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exact Sciences compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Exact Sciences's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exact Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Exact Sciences analyst ratings.
Discovering Exact Sciences: A Closer Look
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Unraveling the Financial Story of Exact Sciences
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Exact Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.12% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exact Sciences's net margin excels beyond industry benchmarks, reaching 0.13%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Exact Sciences's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.03%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Exact Sciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.01% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.82, Exact Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
